You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Monoclonal therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
Has Results
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

NK-T-Cell Lymphoma, Extranodal Trial in Shanghai (4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen

Not yet recruiting
  • NK-T-Cell Lymphoma, Extranodal
  • 4 cycles of ESA regimen with sandwiched radiotherapy
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Sep 29, 2023

Colorectal Cancer Trial in New York (mAb hu3S193)

Terminated
Has Results
  • Colorectal Cancer
  • monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

NSCLC Trial in Guangzhou (PEF, Anti-PD-1 mAb)

Recruiting
  • NSCLC
  • PEF
  • Anti-PD-1 monoclonal antibody
  • Guangzhou, Guangdong, China
    The first Affiliated Hospital of Guangzhou Medical University
Aug 3, 2023

Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial in Rochester (Durvalumab, Radiation Therapy)

Not yet recruiting
  • Lung Non-Small Cell Carcinoma
  • Stage III Lung Cancer AJCC v8
  • Durvalumab
  • Radiation Therapy
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

Completed
Has Results
  • Kidney Cancer
  • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Colorectal Cancer Metastatic Trial (HLX26, HLX10)

Not yet recruiting
  • Colorectal Cancer Metastatic
  • (no location specified)
Oct 14, 2022

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +3 more
  • Clinical Observation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Gastric Cancer Trial in Shanghai (NK510, Tislelizumab,atezolizumab or Trastuzumab)

Enrolling by invitation
  • Gastric Cancer
  • NK510
  • Tislelizumab，atezolizumab or Trastuzumab
  • Shanghai, China
    Shanghai Tenth People's Hospital
Oct 22, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic

Not yet recruiting
  • Locally Advanced Intrahepatic Cholangiocarcinoma
  • +4 more
  • Angiography
  • +8 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Sep 22, 2023

Metastatic Colorectal Carcinoma Trial (Pentoxifylline, FOLFOX, XELOX)

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • (no location specified)
Nov 1, 2023

COVID-19 Trial (GamCoviMab)

Not yet recruiting
  • COVID-19
  • (no location specified)
Feb 6, 2023

Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8

Recruiting
  • Locally Advanced Pancreatic Carcinoma
  • +3 more
  • Biopsy
  • +5 more
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center EDDOP
Nov 30, 2022

Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in New Brunswick (Atezolizumab 1200 MG in 20 ML

Active, not recruiting
  • Refractory Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Atezolizumab 1200 MG in 20 ML Injection
  • +2 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Sep 27, 2022

Solid Tumor, Adult Trial in United States (FT538, Cyclophosphamide, Fludarabine)

Recruiting
  • Solid Tumor, Adult
  • Hackensack, New Jersey
  • +3 more
Apr 14, 2022

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023